Immunotherapy-Chemo cocktail shows promise for tough hodgkin lymphoma
NCT ID NCT03618550
First seen Nov 01, 2025 · Last updated Jun 20, 2026 · Updated 35 times
Summary
This phase 2 trial is testing whether adding the immunotherapy drug pembrolizumab to standard GVD chemotherapy can improve outcomes for people with Hodgkin lymphoma that has returned or not responded to initial treatment. About 257 participants will receive up to 4 cycles of the combination before a stem cell transplant. The study is currently recruiting and will measure how many patients achieve a complete response and how long they remain cancer-free.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HODGKIN LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-••••
Locations
-
City of Hope Cancer Center (Data Collection Only)
NOT_YET_RECRUITINGDuarte, California, 91010, United States
Contact Phone: •••-•••-••••
-
Memorial Sloan Kettering Basking Ridge
RECRUITINGBasking Ridge, New Jersey, 07920, United States
Contact Phone: •••-•••-••••
-
Memorial Sloan Kettering Bergen
RECRUITINGMontvale, New Jersey, 07645, United States
Contact Phone: •••-•••-••••
-
Memorial Sloan Kettering Cancer Center
RECRUITINGNew York, New York, 10065, United States
Contact Phone: •••-•••-••••
Contact
Contact Phone: •••-•••-••••
-
Memorial Sloan Kettering Cancer Center @ Commack
RECRUITINGCommack, New York, 11725, United States
Contact Phone: •••-•••-••••
-
Memorial Sloan Kettering Monmouth
RECRUITINGMiddletown, New Jersey, 07748, United States
Contact Phone: •••-•••-••••
-
Memorial Sloan Kettering Nassau
RECRUITINGUniondale, New York, 11553, United States
Contact Phone: •••-•••-••••
-
Memorial Sloan Kettering Westchester
RECRUITINGHarrison, New York, 10604, United States
Contact Phone: •••-•••-••••
-
Stanford University Medical Center
NOT_YET_RECRUITINGStanford, California, 94305-5408, United States
Contact Phone: •••-•••-••••
-
University of Miami
RECRUITINGMiami, Florida, 33136, United States
Contact Phone: •••-•••-••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
pembrolizumab (an immunotherapy drug) plus GVD chemotherapy (gemcitabine, vinorelbine, liposomal doxorubicin)
What this could lead to
If successful, this combination could offer a more effective way to shrink Hodgkin lymphoma before a stem cell transplant, potentially improving long-term control of the disease.
What could go wrong
This is a mid-stage trial, so results are not yet proven. The combination may cause significant side effects, and not all patients will respond. Long-term benefits are still uncertain.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.